International: +1-347-960-6455
Hypoxia-Inducible Factor (HIF) Inhibitor Therapeutics - Pipeline Analysis 2018

Hypoxia-Inducible Factor (HIF) Inhibitor Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10139 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Others
Select License Type

Hypoxia-inducible factor (HIF) inhibitor inhibits the HIF mediated hypoxic responses. HIF is a transcription factor that activate when there is a decrease in the availability of oxygen in the cellular environment. Hypoxia promotes the formation of blood vessels and this homeostatic system is required in formation of vascular system in the embryo. In conditions like wounds, hypoxia mediate the migration of keratinocytes and restores the epithelium. According to the researchers, the HIF plays a vital role in the development of human body, as they are required by the body to adapt in low oxygen concentration and maintain the metabolism. The therapeutic candidate which acts as an HIF inhibitor has been found to improve the symptoms in anemia, inflammatory disorders and cancer. In addition, HIF inhibitor have also been found to increase the erythropoietin expression and enhance hippocampal memory. In addition, HIF is also essential for immunological responses and is a key physiological regulator of homeostasis, vascularization, and anaerobic metabolism.

Company like FibroGen Inc. is developing roxadustat as a HIF prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease (CKD) and myelodysplastic syndrome (MDS).

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.